Clinical efficacy of methylprednisolone sodium succinate on patients with respiratory distress syndrome
Objective To analyze the clinical effects of different treatment schemes and the differences of various indexes in patients with respiratory distress syndrome.Methods A total of 138 patients with respiratory distress syndrome admitted to Zhongxiang People's Hospital from January 2020 to March 2023 were selected,and they were divided into the routine group(n=69)and the combined treatment group(n=69).Grouping by:random number table method.The routine group was given conventional treatment(antiasthmatic and antispasmodic drugs combined with non-invasive ventilator),while the combined treatment group was given methylprednisolone sodium succinate on the basis of the routine group.The intervention time of all groups was 14 days.The indexes between and within the two groups(The pulmonary function indices,inflammatory factor levels and Murray lung injury score[MLIS],acute physiology and chronic health evaluation Ⅱ[APACHE Ⅱ]score before and after the treatment)were compared.Results Compared with before treatment,the levels of interleukin-6,interleukin-8,tumor necrosis factor-α,and hypersensitive C-reactive protein decreased in both groups after treatment,and the combined treatment group was lower than the conventional group,with statistical significance(P＜0.05).After treatment,the total lung capacity,vital capacity and forced vital capacity in both groups all increased,and the combined treatment group was higher than the conventional group,with statistical significance(P＜0.05).After treatment,the scores of MLIS、APACHE Ⅱ in both groups all decreased,and the combined treatment group was lower than the conventional group,with statistical significance(P＜0.05).Conclusion In the selection of treatment schemes for patients with respiratory distress syndrome,methylprednisolone sodium succinate has more advantages in improving lung function,reducing inflammatory factors and improving prognosis.
万方数据
维普
